Revived cancer drug tested in local clinics for hopeful patients
NCT ID NCT05874193
Summary
This study is testing whether a drug called belantamab mafodotin, combined with a steroid, can be safely given every 6 weeks in local community clinics instead of every 3 weeks at large hospitals. It focuses on patients with multiple myeloma that has returned or stopped responding after at least four prior treatments. The main goal is to see if this less frequent dosing schedule is practical and safe, especially for older or frail patients living in rural areas.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johnston Cancer Center
Smithfield, North Carolina, 27577, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Johnston Hematology and Oncology of Clayton
Clayton, North Carolina, 27570, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Maria Parham Hospital
Henderson, North Carolina, 27536, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Scotland Health Care System
Laurinburg, North Carolina, 28352, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UNC Health Southeastern
Lumberton, North Carolina, 28358, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.